-+ 0.00%
-+ 0.00%
-+ 0.00%

Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance

Benzinga·01/30/2026 21:15:58
Listen to the news

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.